Investment Team

Dr Tom Widmann

Member of the Board, Vinci Life Sciences

Thomas Widmann studied Medicine and Computer Science at the Universities of Heidelberg and Paris, and holds a doctorate in Medicine from the University of Heidelberg. He earned his specialization in cardiology at the University of Geneva in Switzerland. With Hesperion in 1996 and Actelion in 1997, he co-founded two highly successful European Life Science start-up companies.

At Actelion, he was the company's first CEO (until 1999) and played an instrumental role in its IPO and secondary offering, raising a total of CHF 670 million, and in the internationalization of the business and the formation of more than 20 subsidiaries worldwide, including Japan. From 1987 to 1996, Thomas served as Vice President and Head of International Cardiovascular Clinical Research at Hoffmann-La Roche, where he brought three drugs to international markets. Prior to joining Hoffman-La Roche, Thomas had spent six years at the University of California at San Diego as an assistant professor of medicine (cardiology). He formed his first company, Triton Technology, in San Diego, in the early 1980s.

Since 2003, he is a venture partner with Wellington Partners and will become a general partner in the WP-III Life Science Fund being currently established.

In 2004, he co-founded Widmann Associates who is the exclusive partner in Life Science for Vinci Capital. In 2007 he contributed in founding Vinci Life Science where he acts as Chairman of the Board.